Trabectedin for the management of soft-tissue sarcoma

Expert Review of Anticancer Therapy

Volumn 9, Issue 6, 2009, Pages 727-737

  Boudou, Laurence ^a   Baconnier, Mathieu ^a   Blay, Jean Yves ^a,b   Lombard Bohas, Catherine ^a   Cassier, Philippe A ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

Chemotherapy; DNA repair; Drug development; Sarcoma

Indexed keywords

BRCA1 PROTEIN; CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOUBLE STRANDED DNA; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; PACLITAXEL; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; AMINOTRANSFERASE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILE DUCT CARCINOMA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DNA ALKYLATION; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG DNA BINDING; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSFORMATION; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERBILIRUBINEMIA; LEIOMYOSARCOMA; LIVER MICROSOME METABOLISM; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYXOSARCOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHARMACODYNAMICS; PREMEDICATION; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DNA REPAIR; DRUG EFFECT; ENZYMOLOGY; FEMALE; LIVER; METABOLISM; OVARY TUMOR; PATHOPHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CONTROLLED CLINICAL TRIALS AS TOPIC; DIOXOLES; DNA REPAIR; FEMALE; HUMANS; LIVER; NEUTROPENIA; OVARIAN NEOPLASMS; SARCOMA; TETRAHYDROISOQUINOLINES; THROMBOCYTOPENIA; TRANSAMINASES;

EID: 68849099175     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.28     Document Type: Article

References (59)

1. Rinehart KL. Antitumor compounds from tunicates. Med. Res. Rev. 20(1), 1-27 (2000).
2. Cuevas C, Perez M, Martin MJ et al. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org. Lett. 2(16), 2545-2548 (2000).
3. David-Cordonnier MH, Gajate C, Olmea O et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem. Biol. 12(11), 1201-1210 (2005).
4. Takebayashi Y, Pourquier P, Zimonjic DB et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7(8), 961-966 (2001).
5. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 62(12), 3377-3381 (2002).
6. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 66(16), 8155-8162 (2006).
7. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin. Cancer Res. 7(1), 185-191 (2001).
8. Soares DG, Escargueil AE, Poindessous V et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl Acad. Sci. USA 104(32), 13062-13067 (2007).
9. Guirouilh-Barbat J, Redon C, Pommier Y. Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11 - Rad50 - Nbs1 complex. Mol. Biol. Cell 19(9), 3969-3981 (2008).
10. Taamma A, Misset JL, Riofrio M et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol. 19(5), 1256-1265 (2001).
11. Ryan DP, Supko JG, Eder JP et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin. Cancer Res. 7(2), 231-242 (2001).
12. Twelves C, Hoekman K, Bowman A et al. Phase I and pharmacokinetic study of Yondelis (ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur. J. Cancer 39(13), 1842-1851 (2003).
13. Reid JM, Kuffel MJ, Ruben SL et al. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin. Cancer Res. 8(9), 2952-2962 (2002).
14. Sparidans RW, Rosing H, Hillebrand MJ et al. Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man. Anticancer Drugs 12(8), 653-666 (2001).
15. Brandon EF, Sparidans RW, Guijt KJ et al. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, trabectidin), a novel marine anti-cancer drug. Invest. New Drugs 24(1), 3-14 (2006).
16. Beumer JH, Buckle T, Ouwehand M et al. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Invest. New Drugs 25(1), 1-7 (2007).
17. Delaloge S, Yovine A, Taamma A et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients: preliminary evidence of activity. J. Clin. Oncol. 19(5), 1248-1255 (2001).
18. Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol. 22(5), 890-899 (2004).
19. Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol. 22(8), 1480-1490 (2004).
20. LeCesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23(3), 576-584 (2005).
21. Blay JY, Le CA, Verweij J et al. A Phase II study of ET-743/ trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 40(9), 1327-1331 (2004).
22. Ryan DP, Puchalski T, Supko JG et al. A Phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 7(6), 531-538 (2002).
23. Huygh G, Clement PM, Dumez H et al. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma 56282 (2006).
24. Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J. Clin. Oncol. 23(24), 5484-5492 (2005).
25. Samuels BL, Rushing D, Chawla SP et al. Randomized Phase II study of trabectedin (ET-743) given by two different dosing schedules in patients with leiomyosarcoma or liposarcomas refractory to conventional doxorubicin and ifosfamide chemotherapy. ASCO Meeting Abstracts 22(14 Suppl.), 9000 (2004).
26. Morgan JA, Le Cesne A, Chawla S et al. Randomized Phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I). ASCO Meeting Abstracts 25(18 Suppl.), 10060 (2007).
27. Grosso F, Demetri GD, Blay JY et al. Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. ASCO Meeting Abstracts 24(18 Suppl.), 9511 (2006).
28. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8(7), 595-602 (2007).
29. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363(6430), 640-644 (1993).
30. Antonescu CR, Tschernyavsky SJ, Decuseara R et al. Prognostic impact of P53 status, TLS - CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin. Cancer Res. 7(12), 3977-3987 (2001).
31. Grosso F, Forni C, Frapolli R et al. Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. ASCO Meeting Abstracts 25(18 Suppl.), 10000 (2007).
32. Forni C, Minuzzo M, Virdis E et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol. Cancer Ther. 8(2), 449-457 (2009).
33. Patel SR, Burgess MA, Plager C, Papadopoulos NE, Linke KA, Benjamin RS. Myxoid liposarcoma. Experience with chemotherapy. Cancer 74(4), 1265-1269 (1994).
34. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur. J. Cancer. 41(18), 2853-2860 (2005).
35. Pitson G, Robinson P, Wilke D et al. Radiation response: an additional unique signature of myxoid liposarcoma. Int. J. Radiat. Oncol. Biol. Phys. 60(2), 522-526 (2004).
36. Schoffski P, Casali PG, Taron M et al. DNA repair functionality modulates the clinical outcome of patients. ASCO Meeting Abstracts 24(18 Suppl.), 9522 (2006).
37. Villalona-Calero MA, Eckhardt SG, Weiss G et al. A Phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin. Cancer Res. 8(1), 75-85 (2002).
38. Gomez J, Lopez-Lazaro L, Guzman C et al. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. ASCO Meeting Abstracts 19, 727 (2000).
39. Donald S, Verschoyle RD, Greaves P et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res. 63(18), 5902-5908 (2003).
40. Grosso F, Dileo P, Sanfilippo R et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur. J. Cancer 42(10), 1484-1490 (2006).
41. McCune JS, Hawke RL, LeCluyse EL et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin. Pharmacol. Ther. 68(4), 356-366 (2000).
42. Lee JK, Leslie EM, Zamek-Gliszczynski MJ, Brouwer KL. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicol. Appl. Pharmacol. 228(1), 17-23 (2008).
43. Salazar R, Pardo B, Majem M et al. Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3h/q3w) in patients with advanced cancer and hepatic function disorder. ASCO Meeting Abstracts 24(18 Suppl.), 2080 (2006).
44. Messersmith WA, Jimeno A, Ettinger D et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 63(1), 181-188 (2008).
45. Von Mehren M, Schilder RJ, Cheng JD et al. A Phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann. Oncol. 19(10), 1802-1809 (2008).
46. Monk BJ, Herzog T, Kaye S et al. A randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian carcinoma (OC). Ann Oncol. 19(Suppl. 8), LBA4 (2009).
47. Blay JY, Von Mehren M, Samuels BL et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin. Cancer Res. 14(20), 6656-6662 (2008).
48. Sessa C, Perotti A, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur. J. Cancer. 45(7), 1153-1161 (2009).
49. Von Mehren M, Buck D, Temmer E, Elsayed YA, Cohen RB. Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies. ASCO Meeting Abstracts 24(18 Suppl.), 2068 (2006).
50. Gore L, Rivera E, Lavallee K et al. Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies. ASCO Meeting Abstracts 24(18 Suppl.), 2079 (2006).
51. Grosso F, Demetri GD, Blay JY et al. Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. ASCO Meeting Abstracts 24(18 Suppl.), 9511 (2006).
52. Schoffski P, Casali PG, Taron M et al. DNA repair functionality modulates the clinical outcome of patients. ASCO Meeting Abstracts 24(18 Suppl.), 9522 (2006).
53. Bay JO, Ray-Coquard I, Fayette J et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int. J. Cancer 119(3), 706-711 (2006).
54. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol. 20(12), 2824-2831 (2002).
55. Maki RG, Keohan ML, Undevia SD et al. Updated results of a Phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. ASCO Meeting Abstracts 26(15 Suppl.), 10531 (2008).
56. Ryan CW, Von Mehren M, Rankin CJ et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. ASCO Meeting Abstracts 26(15 Suppl.), 10532 (2008).
57. Sleijfer S, Papai Z, Le Cesne A et al. Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043. ASCO Meeting Abstracts 25(18 Suppl.), 10031 (2007).
58. Grosso F, Sanfilippo RG, Dileo P et al. Long-term benefit from trabectedin (T) in myxoid liposarcoma (MLS) patients. ASCO Meeting Abstracts 26(15 Suppl.), 10582 (2008).
59. Schoffski P, Casali PG, Taron M et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). ASCO Meeting Abstracts 24(18 Suppl.), 9522 (2006).